1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd.

6794.TW
UnicoCell Biomed Co., Ltd.TW flagTaiwan Stock Exchange
83.20
TWD
- -
- -
5.29BMarket Cap
UnicoCell Biomed Co., Ltd.
6794.TW
(Taiwan Stock Exchange)

Recent

price

83.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.18
0.34
0.51
0.11
0.22
0.35
0.46
0.56
- -
0.42
Revenue per Share
- -
-2.49
-3.3
-3.05
-2.27
-2.2
-1.56
-1.62
- -
-1.5
Basic EPS, GAAP
-1.31
-4.2
-4.18
-4.16
-2.26
-1.88
-1.52
-1.17
- -
-1.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
14.71
5.84
3.49
1.07
-0.11
0.83
-0.37
- -
-1.4
Book Value per Share
4.07
16.67
9.58
9.57
6.92
8.04
11.08
11.93
- -
14.47
Tangible Book Value per Share
34
16
31
36
38
41
54
57
- -
60
Basic Weighted Avg Shares
6
5
16
4
8
14
25
32
30
25
Sales/Revenue/Turnover
-739.17
-1,256.52
-642.23
-2,796.43
-1,068.08
-639.78
-391.55
-322.82
-432.39
-398.92
Operating Margin (%)
5
5
21
24
26
24
26
28
21
15
Depreciation Expense
- -
-41
-101
-109
-86
-91
-84
-93
-115
-90
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-737.58
-641.41
-2,742.57
-1,056.3
-633.15
-342.06
-291.94
-381.48
-360.21
Profit Margin (%)
126
249
224
228
142
221
490
565
766
766
Working Capital
- -
- -
35
24
13
61
68
62
56
56
LT Debt
137
273
294
343
263
334
596
685
865
865
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-33.83
-48.29
-71.94
-104.22
- -
- -
- -
- -
-37,866.2
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
6
- -
6
LT Borrowings
- -
- -
- -
LT Finance Leases
59
- -
56
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
64
Market Capitalization
3,704
4,832
5,358

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
655
- -
787
Cash, Cash Equivalents & STI
618
- -
752
Accounts Receivable, Net
2
- -
3
Inventories
8
- -
8
Total Current Liabilities
19
- -
21
Payables & Accruals
- -
- -
- -
ST Debt
6
- -
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.67%
26.41%
Free Cash Flow
- -
-4.03%
44.35%
Net Income, GAAP
- -
2.19%
23.38%
Sales/Revenue/Turnover
- -
55.26%
-5.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
4
8
5
8
25
2024
3
4
15
11
32
2025
10
9
- -
6
30

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.36
-0.27
-0.48
- -
-1.56
2024
-0.57
-0.45
-0.23
- -
-1.62
2025
-0.48
-0.52
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Silence Therapeutics plc (SLN.L)
Seaport Therapeutics, Inc. Common Stock (SPTX)
Genelux Corporation (GNLX)
MaaT Pharma S.A. (MAAT.PA)
Fusion Antibodies plc (FAB.L)
Avacta Group Plc (AVCTF)
Business
UnicoCell Biomed Co., Ltd. (6794.TW) develops stem cell therapies and regenerative medicine solutions focused on adipose-derived mesenchymal stem cells. The company offers ELIXCYTE, an allogeneic stem cell product in Phase 2 clinical trials for knee osteoarthritis and chronic kidney disease; stem cell secretome and high-concentration exosome products for skin care, hair restoration, and therapeutic applications; autologous stem cell therapy for burns and wound healing; an allogeneic adipose stem cell bank serving clinical trials and research; and customized CDMO services for cell therapy production from its PIC/S GMP-certified pilot plant. UnicoCell Biomed operates primarily in Taiwan with exports to Japan and expansion into South Korea; it is headquartered in Taipei and was incorporated in 2018 as a spin-off from DV BioMed group founded in 2011. Recent developments include receipt of US FDA Fast Track Designation for ELIXCYTE in chronic kidney disease in March 2025; approval from Taiwan's Ministry of Health and Welfare for extension of its Human Organ Bank license and PIC/S GMP pilot plant certification in March 2025; transfer of stock listing to the Taiwan Stock Exchange General Board in July 2025; a strategic partnership with New Cell Bio in August 2025 to enter the South Korean regenerative medicine market with stem cell and exosome products; and a domestic alliance with Mentor Group, Taiwan's largest hair salon chain, for exosome-based hair care in February 2025.